U.S. markets closed

Knight Therapeutics Inc. (GUD.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
5.250.00 (0.00%)
At close: 4:00PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.25
Open5.24
Bid5.25 x 0
Ask5.26 x 0
Day's Range5.23 - 5.30
52 Week Range4.88 - 7.45
Volume105,837
Avg. Volume331,888
Market Cap661.553M
Beta (5Y Monthly)0.67
PE Ratio (TTM)14.42
EPS (TTM)0.36
Earnings DateAug 11, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Who Has Been Buying Knight Therapeutics Inc. (TSE:GUD) Shares?
      Simply Wall St.

      Who Has Been Buying Knight Therapeutics Inc. (TSE:GUD) Shares?

      It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

    • Knight Therapeutics Announces Closing of Previously Announced Acquisition and Exclusive License to Exelon® in Canada and Latin America
      GlobeNewswire

      Knight Therapeutics Announces Closing of Previously Announced Acquisition and Exclusive License to Exelon® in Canada and Latin America

      MONTREAL, May 26, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, is pleased to announce that it has completed the acquisition of the exclusive rights to manufacture, market and sell Exelon® (rivastigmine Patch, Capsules and Solution) in Canada and Latin America (the “Territory”), as well as an exclusive license to use the intellectual property and the Exelon trademark, from Novartis within the Territory. Knight has paid USD $168 million in cash and will pay an additional milestone payment of up to USD $12 million upon the achievement of certain conditions. Knight has entered into a transition service agreement until transfer of marketing authorizations, on a country by country basis during which Knight will receive a net profit transfer. Knight will begin distributing Exelon upon transfer of marketing authorizations, on a country by country basis. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com. Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law. Investor Contact: Knight Therapeutics Inc. Samira SakhiaArvind UtchanahPresident and Chief Operating OfficerChief Financial OfficerT: 514-484-4483T: 514-484-4483F: 514-481-4116F: 514-481-4116info@knighttx.cominfo@knighttx.comwww.gud-knight.comwww.gud-knight.com/

    • Knight to Present at the Jefferies 2021 Virtual Healthcare Conference
      GlobeNewswire

      Knight to Present at the Jefferies 2021 Virtual Healthcare Conference

      MONTREAL, May 25, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Operating Officer, is scheduled to present at the Jefferies 2021 Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:30 AM ET. A live webcast of the event will be available at the following link: Event. A copy of the presentation will be available at www.gud-knight.com. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com. Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law. Investor Contact: Knight Therapeutics Inc.Samira SakhiaArvind UtchanahPresident and Chief Operating OfficerChief Financial OfficerT: 514-484-4483T: 514-484-4483F: 514-481-4116F: 514-481-4116info@knighttx.cominfo@knighttx.comwww.gud-knight.comwww.gud-knight.com